Vladimir Vainstein

1.1k total citations
51 papers, 723 citations indexed

About

Vladimir Vainstein is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Vladimir Vainstein has authored 51 papers receiving a total of 723 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Hematology, 20 papers in Oncology and 14 papers in Molecular Biology. Recurrent topics in Vladimir Vainstein's work include Acute Myeloid Leukemia Research (15 papers), Neutropenia and Cancer Infections (9 papers) and Chronic Myeloid Leukemia Treatments (8 papers). Vladimir Vainstein is often cited by papers focused on Acute Myeloid Leukemia Research (15 papers), Neutropenia and Cancer Infections (9 papers) and Chronic Myeloid Leukemia Treatments (8 papers). Vladimir Vainstein collaborates with scholars based in Israel, United States and Germany. Vladimir Vainstein's co-authors include Zvia Agur, Yuri Kogan, Natalie Kronik, Zoya Gluzman‐Poltorak, Roland B. Walter, Nurith Hiller, Boaz Nachmias, S. Nahum Goldberg, Natalia Simanovsky and Malena Cohen‐Cymberknoh and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Vladimir Vainstein

44 papers receiving 686 citations

Peers

Vladimir Vainstein

ONCOL

HEMAT

RNMI

Ofrat Beyar‐Katz Israel

Christine‐Ivy Liacos Greece

Yang Cao China

Anne Devys France

Paolo Alberto Paciucci United States

Patrick Ellsworth United States

Jacqueline S. Hart United States

Qing Cheng China

Ching‐Chan Lin Taiwan

Alexandros Spyridonidis Greece

Ofrat Beyar‐Katz Israel

Vladimir Vainstein

444 ×1.6

ONCOL

136 ×0.6

HEMAT

166 ×0.7

7 ×0.1

14 ×0.1

RNMI

Citations per year, relative to Vladimir Vainstein Vladimir Vainstein (= 1×) peers Ofrat Beyar‐Katz

Countries citing papers authored by Vladimir Vainstein

Since Specialization

Citations

This map shows the geographic impact of Vladimir Vainstein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vladimir Vainstein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vladimir Vainstein more than expected).

Fields of papers citing papers by Vladimir Vainstein

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vladimir Vainstein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vladimir Vainstein. The network helps show where Vladimir Vainstein may publish in the future.

Co-authorship network of co-authors of Vladimir Vainstein

This figure shows the co-authorship network connecting the top 25 collaborators of Vladimir Vainstein. A scholar is included among the top collaborators of Vladimir Vainstein based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vladimir Vainstein. Vladimir Vainstein is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Vainstein, Vladimir, P. Milani, Giovanni Palladini, et al.. (2024). Belantamab Mafodotin in Relapsed/Refractory AL Amyloidosis: Real-World Multi-Center Experience and Review of the Literature. Acta Haematologica. 148(4). 419–426. 3 indexed citations

Aumann, Shlomzion, Vladimir Vainstein, Ariela Arad, et al.. (2024). DNMT3A, TET2, and ASXL1 (DTA) Mutations Are Associated with Thrombosis and Bleeding in Patients with Myeloproliferative Neoplasms. Blood. 144(Supplement 1). 3189–3189. 1 indexed citations

Canaani, Jonathan, Daniel A. Pollyea, Marc Schwartz, et al.. (2023). Venetoclax‐based salvage therapy for adult patients with relapsed/refractory acute lymphoblastic leukemia. European Journal Of Haematology. 111(3). 365–372. 6 indexed citations

Nachmias, Boaz, Svetlana Krichevsky, Moshe E. Gatt, et al.. (2023). Standardization of Molecular MRD Levels in AML Using an Integral Vector Bearing ABL and the Mutation of Interest. Cancers. 15(22). 5360–5360. 2 indexed citations

Vainstein, Vladimir, Batia Avni, Sigal Grisariu, et al.. (2023). Clonal Myeloid Dysplasia Following CAR T-Cell Therapy: Chicken or the Egg?. Cancers. 15(13). 3471–3471. 8 indexed citations

Aumann, Shlomzion, Boaz Nachmias, Dina Ben Yehuda, et al.. (2023). Risk factors and outcomes of COVID‐19 in adult patients with hematological malignancies: A single‐center study showing lower than expected rates of hospitalization and mortality. European Journal Of Haematology. 111(1). 135–145. 1 indexed citations

Vainstein, Vladimir, Paolo Milani, Giovanni Palladini, et al.. (2023). Belantamab Mafodotin in Relapse/Refractory AL Amyloidosis- Real-Life Multi-Center Experience. Blood. 142(Supplement 1). 6763–6763. 2 indexed citations

Aumann, Shlomzion, et al.. (2022). The Emerging Role of Venetoclax-Based Treatments in Acute Lymphoblastic Leukemia. International Journal of Molecular Sciences. 23(18). 10957–10957. 21 indexed citations

Wolach, Ofir, Liat Shargian, Moshe Yeshurun, et al.. (2022). Venetoclax in combination with FLAG-IDA-based protocol for patients with acute myeloid leukemia: a real-world analysis. Annals of Hematology. 101(8). 1719–1726. 21 indexed citations

10.

Shimony, Shai, Jonathan Canaani, Boaz Nachmias, et al.. (2022). Gilteritinib monotherapy for relapsed/refractory FLT3 mutated acute myeloid leukemia: a real-world, multi-center, matched analysis. Annals of Hematology. 101(9). 2001–2010. 10 indexed citations

11.

Nachmias, Boaz, Svetlana Krichevsky, Dvora Filon, et al.. (2022). Monitoring Minimal Residual Disease in <b><i>RUNX1</i></b>-Mutated Acute Myeloid Leukemia. Acta Haematologica. 145(6). 642–649. 4 indexed citations

12.

Hiller, Nurith, S. Nahum Goldberg, Malena Cohen‐Cymberknoh, Vladimir Vainstein, & Natalia Simanovsky. (2021). Lymphadenopathy Associated With the COVID-19 Vaccine. Cureus. 13(2). e13524–e13524. 44 indexed citations

13.

Majewski, Matthäus, Patrick Ostheim, Zoya Gluzman‐Poltorak, et al.. (2021). Gene expression changes in male and female rhesus macaque 60 days after irradiation. PLoS ONE. 16(7). e0254344–e0254344. 2 indexed citations

14.

Ganzel, Chezi, Ron Ram, Alexander Gural, et al.. (2020). Venetoclax is safe and efficacious in relapsed/refractory AML. Leukemia & lymphoma. 61(9). 2221–2225. 30 indexed citations

15.

Vainstein, Vladimir, et al.. (2015). Mathematical model of radiation effects on thrombopoiesis in rhesus macaques and humans. Journal of Theoretical Biology. 383. 44–60. 4 indexed citations

16.

Vainstein, Vladimir, et al.. (2014). Single low-dose rHuIL-12 safely triggers multilineage hematopoietic and immune-mediated effects. Experimental Hematology and Oncology. 3(1). 11–11. 23 indexed citations

17.

Vainstein, Vladimir, et al.. (2012). Analyzing transformation of myelodysplastic syndrome to secondary acute myeloid leukemia using a large patient database. American Journal of Hematology. 87(9). 853–860. 25 indexed citations

18.

Ariad, Samuel, Offer Amir, Wilmosh Mermershtain, et al.. (2012). Personalising docetaxel and G-CSF schedules in cancer patients by a clinically validated computational model. British Journal of Cancer. 107(5). 814–822. 23 indexed citations

19.

Velden, Vincent H. J. van der, et al.. (2011). Targeted Drug Delivery by Gemtuzumab Ozogamicin: Mechanism-Based Mathematical Model for Treatment Strategy Improvement and Therapy Individualization. PLoS ONE. 6(9). e24265–e24265. 27 indexed citations

20.

Zadik, Yehuda, et al.. (2010). Cytotoxic Chemotherapy-induced Odontalgia: A Differential Diagnosis for Dental Pain. Journal of Endodontics. 36(9). 1588–1592. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact